nivolumab
nivolumab
Overview
Nivolumab (brand name Opdivo) is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, a key immune checkpoint expressed on the surface of T-lymphocytes. By binding to PD-1 and blocking its interaction with its ligands PD-L1 (Programmed Death-Ligand 1) and PD-L2, nivolumab prevents T-cell suppression and restores the immune system's capacity to recognize and destroy cancer cells. This mechanism disrupts a central immune evasion strategy exploited by many tumor types, making nivolumab one of the foundational agents of modern cancer immunotherapy. Developed by Bristol-Myers Squibb and first approved by the FDA in 2014, nivolumab has since received regulatory approval across a broad range of malignancies including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), esophageal cancer, bladder cancer, colorectal cancer, and classical Hodgkin lymphoma, among others.
Nivolumab is frequently used as monotherapy or in combination with the anti-CTLA-4 antibody ipilimumab, a pairing that delivers dual checkpoint inhibitor. This combination exploits complementary and non-redundant mechanisms: PD-1 blockade primarily reinvigorates exhausted effector T-cells in the tumor microenvironment, while CTLA-4 blockade with ipilimumab promotes T-cell priming and expansion in lymphoid tissue. Together, they produce synergistic antitumor activity, though often at the cost of increased immune-related adverse events (irAEs). Biomarkers such as PD-L1 expression, tumor mutational burden, and microsatellite instability are actively investigated as predictors of response, though their clinical utility varies across tumor types.
Focus of Latest Publications
Recent investigations have demonstrated the efficacy of nivolumab across diverse tumor types when combined with complementary therapeutic agents. Dual immune checkpoint inhibition with nivolumab plus ipilimumab has emerged as a particularly promising strategy, showing superior overall survival and response rates compared to conventional tyrosine kinase inhibitors in unresectable hepatocellular carcinoma and establishing clinical benefit in metastatic renal cell carcinoma, esophageal squamous cell carcinoma, melanoma brain metastases, and rare malignancies including extrapulmonary neuroendocrine carcinomas and uveal melanoma. Nivolumab combined with the antiangiogenic agent cabozantinib demonstrated a 45.2% objective response rate and 93.6% disease control rate in advanced non-clear cell renal cell carcinoma, with durable benefit across diverse histologic subtypes. Additionally, nivolumab integrated into neoadjuvant and concurrent chemoradiotherapy regimens has shown efficacy in locally advanced esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and muscle-invasive bladder cancer, while combination with stereotactic ablative body radiation therapy enhanced activity in advanced non-small cell lung cancer progressing after prior chemotherapy.
Real-world studies confirm the clinical utility of immunotherapy rechallenge strategies and long-term treatment sequencing in previously treated patients. In metastatic non-small cell lung cancer and renal cell carcinoma, nivolumab rechallenge after prior immunotherapy-based combinations has demonstrated feasibility and durable disease control in routine clinical practice over extended follow-up periods. Neoadjuvant nivolumab-based regimens in melanoma and non-small cell lung cancer have yielded favorable long-term survival outcomes, with 5-year data from melanoma stage III patients showing 86% overall survival and 79% distant metastasis-free survival following neoadjuvant ipilimumab plus nivolumab, particularly in patients achieving major pathologic response.
Biomarkers and host factors significantly influence nivolumab efficacy and treatment outcomes. Programmed cell death ligand 1 (PD-L1) expression, tumor mutational burden, and interferon-gamma signature emerge as predictive biomarkers associated with superior response and survival. Host-related factors including COVID-19 vaccination type and concurrent use of proton pump inhibitors have been shown to influence treatment efficacy in metastatic non-small cell lung cancer and esophageal cancer, respectively, with preliminary evidence suggesting that probiotics may restore therapeutic benefit in patients receiving concurrent acid-suppressive therapy. Molecular investigations of nivolumab binding kinetics reveal temperature-dependent interactions with PD-1, with potential implications for managing therapy-associated fever and inflammatory responses.
The safety profile of nivolumab-based combinations remains generally manageable across studied populations. Grade 3–4 treatment-emergent adverse events occurred in 46.8% of patients receiving cabozantinib plus nivolumab in renal cell carcinoma, with only 6.5% experiencing treatment discontinuation due to toxicity. Immune-related adverse events, including folliculitis, pneumonitis, and endocrinopathies such as hypothyroidism, have been documented as expected complications of checkpoint inhibition. Notably, preserved gonadal function and fertility were observed up to 24 months following nivolumab-AVD therapy in classic Hodgkin lymphoma, and patient-reported quality of life improvements have been documented with nivolumab-based chemoradiotherapy in nasopharyngeal carcinoma.